Presymptomatic testing using DNA markers for individuals at risk for familial multiple endocrine neoplasia 2A

Jay B. Lichter, Jingshi Wu, Myron Genel, Stuart D Flynn, Andrew J. Pakstis, Judith R. Kidd, Kenneth K. Kidd

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The carrier status of 39 at-risk individuals in 6 multiple endocrine neoplasia 2A families was determined using a DNA based test. We were able to calculate a virtual diagnosis (probability >95%) for 77% of the individuals and a probable diagnosis (probability >90%) for 90% of the individuals. This study points out some of the problems of specific pedigree structures that can affect the risk calculation. This study further shows that no single test based on either biochemistry, pathology, or genetics can consistently and unambiguously produce a presymptomatic diagnosis. We also describe two specific exampies where DNA testing has helped to resolve clinical uncertainties in at-risk individuals.

Original languageEnglish (US)
Pages (from-to)368-373
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume74
Issue number2
StatePublished - Feb 1992
Externally publishedYes

Fingerprint

Multiple Endocrine Neoplasia
Genetic Markers
DNA
Testing
Biochemistry
Pathology
Pedigree
Uncertainty

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Presymptomatic testing using DNA markers for individuals at risk for familial multiple endocrine neoplasia 2A. / Lichter, Jay B.; Wu, Jingshi; Genel, Myron; Flynn, Stuart D; Pakstis, Andrew J.; Kidd, Judith R.; Kidd, Kenneth K.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 74, No. 2, 02.1992, p. 368-373.

Research output: Contribution to journalArticle

Lichter, Jay B. ; Wu, Jingshi ; Genel, Myron ; Flynn, Stuart D ; Pakstis, Andrew J. ; Kidd, Judith R. ; Kidd, Kenneth K. / Presymptomatic testing using DNA markers for individuals at risk for familial multiple endocrine neoplasia 2A. In: Journal of Clinical Endocrinology and Metabolism. 1992 ; Vol. 74, No. 2. pp. 368-373.
@article{c30281bcbed74fa387bb522ea5149384,
title = "Presymptomatic testing using DNA markers for individuals at risk for familial multiple endocrine neoplasia 2A",
abstract = "The carrier status of 39 at-risk individuals in 6 multiple endocrine neoplasia 2A families was determined using a DNA based test. We were able to calculate a virtual diagnosis (probability >95{\%}) for 77{\%} of the individuals and a probable diagnosis (probability >90{\%}) for 90{\%} of the individuals. This study points out some of the problems of specific pedigree structures that can affect the risk calculation. This study further shows that no single test based on either biochemistry, pathology, or genetics can consistently and unambiguously produce a presymptomatic diagnosis. We also describe two specific exampies where DNA testing has helped to resolve clinical uncertainties in at-risk individuals.",
author = "Lichter, {Jay B.} and Jingshi Wu and Myron Genel and Flynn, {Stuart D} and Pakstis, {Andrew J.} and Kidd, {Judith R.} and Kidd, {Kenneth K.}",
year = "1992",
month = "2",
language = "English (US)",
volume = "74",
pages = "368--373",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Presymptomatic testing using DNA markers for individuals at risk for familial multiple endocrine neoplasia 2A

AU - Lichter, Jay B.

AU - Wu, Jingshi

AU - Genel, Myron

AU - Flynn, Stuart D

AU - Pakstis, Andrew J.

AU - Kidd, Judith R.

AU - Kidd, Kenneth K.

PY - 1992/2

Y1 - 1992/2

N2 - The carrier status of 39 at-risk individuals in 6 multiple endocrine neoplasia 2A families was determined using a DNA based test. We were able to calculate a virtual diagnosis (probability >95%) for 77% of the individuals and a probable diagnosis (probability >90%) for 90% of the individuals. This study points out some of the problems of specific pedigree structures that can affect the risk calculation. This study further shows that no single test based on either biochemistry, pathology, or genetics can consistently and unambiguously produce a presymptomatic diagnosis. We also describe two specific exampies where DNA testing has helped to resolve clinical uncertainties in at-risk individuals.

AB - The carrier status of 39 at-risk individuals in 6 multiple endocrine neoplasia 2A families was determined using a DNA based test. We were able to calculate a virtual diagnosis (probability >95%) for 77% of the individuals and a probable diagnosis (probability >90%) for 90% of the individuals. This study points out some of the problems of specific pedigree structures that can affect the risk calculation. This study further shows that no single test based on either biochemistry, pathology, or genetics can consistently and unambiguously produce a presymptomatic diagnosis. We also describe two specific exampies where DNA testing has helped to resolve clinical uncertainties in at-risk individuals.

UR - http://www.scopus.com/inward/record.url?scp=0026511019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026511019&partnerID=8YFLogxK

M3 - Article

C2 - 1346145

AN - SCOPUS:0026511019

VL - 74

SP - 368

EP - 373

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -